The Efficacy of Guizhi Fuling Capsule or Kuntai Capsule Combined With Diane-35 and Metformin in Polycystic Ovary Syndrome: A Systematic Review and Meta-Analysis
Abstract
Background: Polycystic ovary syndrome (PCOS) is one of the most common reproductive endocrine metabolic diseases. Combined use of metformin and diane-35 has better curative effect in regulating serum hormone level (LH, FSH, T and E2) than using metformin alone. Traditional Chinese medicine (TCM) can also be used to treat PCOS. According to some studies, the combined use of metformin and diane-35 and TCM have achieved better curative effect than combining metformin and diane-35 in the treatment of patients with PCOS. Methods: Computerized searches of the science, Medline, VIP, Wan Fang and China HowNet (CNKI) databases were conducted to identify eligible randomized controlled trials (RCTs) from the data obtained up to March 1, 2022. The Cochrane Collaboration risk of bias tool was used to assess the risk of bias in individual RCTs, and R software( version 4.0.3) was used for data statistical analysis. Results: Nine RCTs involving 1035 patients were included. Comparing to D+M, significant reduce of LH( mean difference [MD]: −1.93, 95% confidence interval [CI]: -3.44, -0.42;Unit:U/L P＜0.01; I2=89%)、T(MD: -1.44, 95%CI -2.59, -0.30;Unit:nmol/L P＜0.01; I2=98%) and significant increase of E2(MD: 31.43, 95%CI 24.54, 38.33;Unit:pmol/L P＜0.01; I2=96%) were shown in TCM+D+M. Comparing to D+M, TCM+D+M group has higher ovulation rate(RR 1.14 95%CI 1.07,1.22; P=0.42; I2=0%) and higher pregnancy rate(RR 1.29 95%CI 1.15,1.44; P=0.37; I2=7%). There is no significant difference between the…
How strong is the evidence?
Evidence Hub reads this as a meta-analysis, done in people. Its evidence level is 1 of 5 (Highest · pooled evidence). Pooled evidence from several studies sits at the top of the evidence pyramid. Reported size: 1,035 participants or records.
Read the paper
Related studies
- Increased expression of circulating miRNA-93 in women with polycystic ovary syndrome may represent a novel, non-invasive biomarker for diagnosis
- Identification of key genes associated with polycystic ovary syndrome (PCOS) and ovarian cancer using an integrated bioinformatics analysis
- Identification of key pathways and genes in polycystic ovary syndrome via integrated bioinformatics analysis and prediction of small therapeutic molecules
- Regulation of Androgen Receptor Expression Alters AMPK Phosphorylation in the Endometrium: In Vivo and In Vitro Studies in Women with Polycystic Ovary Syndrome
- Effect of oral administration of low-dose follicle stimulating hormone on hyperandrogenized mice as a model of polycystic ovary syndrome
- Systems pharmacology to investigate the interaction of berberine and other drugs in treating polycystic ovary syndrome
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.